期刊文献+

重组抗CD52人源化单克隆抗体ELISA检测方法的建立

Development of Enzyme Linked Immunosorbent Assay Method for Detection of rh-anti-CD52xim Ab
下载PDF
导出
摘要 目的:建立一种灵敏、特异、快速的ELISA方法,用于检测食蟹猴血清中重组抗CD52单克隆抗体的含量。方法:采用双抗夹心ELISA法对重组抗CD52单克隆抗体进行定量。以猴血清吸附的羊抗人Ig G作为包被抗体,稀释的猴血清吸附的羊抗人Ig G-HRP(二抗)作为检测抗体,加入底物显色剂后在酶标仪上读取D450nm值。结果:建立并确证了检测重组抗CD52单克隆抗体的ELISA方法,方法的线性范围为7.81~500 ng/m L,定量下限为7.81 ng/m L,板内及板间精密度和准确度均在±15%以内,室温、冻融、稀释效应稳定性良好。结论:方法学验证表明ELISA法测定食蟹猴血清中重组抗CD52单克隆抗体浓度的特异性、精密度和准确度均满足新生物制药临床前药代动力学研究指导原则要求,可用于重组抗CD52单克隆抗体的检测。 Objective: To establish a specific, sensitive and rapid enzyme linked immunosorbent assay(ELISA) method for detection of rh-anti-CD52ximAb in rhesus monkey serum. Methods: This study employed the quantita- tive sandwich enzyme immunoassay technique. The assay method utilized sheep anti-human IgG that had been ad- sorbed against cynomolgus monkey serum for capture as well as detection of rh-anti-CD52ximAb. Following that, color was developed by the substrate solution and the reaction was stopped by stop solution. Then the plate was analyzed with a microplate reader at a wavelength of 450 nm. Results: An ELISA assay was developed with a wide dynamic range of concentrations from 7.81 to 500 ng/mL with a lowest quantification of 7.81 ng/mL, both ac- curacy of the intra- and inter-assay were less than 15%. Meanwhile, well stability of rh-anti-CD52ximAb was shown by evaluation on different storage conditions and dilution with serum. Conclusion: This method is highly sensitive, accurate, specific, and reproducibility, which was proven to be a feasible quantitative method for the de- tection of rh-anti-CD52ximAb.
出处 《生物技术通讯》 CAS 2015年第5期667-671,共5页 Letters in Biotechnology
关键词 重组抗CD52单克隆抗体 酶联免疫吸附法 药代动力学 rh-anti-CD52ximAb ELISA pharmacokinetics
  • 相关文献

参考文献12

  • 1Sabatlini E, Baeei F. Sagamoso C. et al. WHO elassifica- lion of olhaemalopoictic and lymphoid tissues in 2008: an owrview[J]. Pathologiea. 2010.102(3):83-87. 被引量:1
  • 2StatRite: estimated new cases for the bur major leukemias. 2008[J]. J Natl Caner lnst, 2009,101(6):371. 被引量:1
  • 3屈浩 ,廖晓龙 .CD52抗原的研究进展及其抗体在临床中的应用[J].国外医学(免疫学分册),2005,28(6):369-373. 被引量:3
  • 4Rowan . Tire J, Tpley P. el al. Cross-linking of the CAM- PATH-1 antigen(CD52) mediales growth inhibition in human B- and T-lymphonm eelllines, and subsequent emergence of CD52-defieient cells[J]. Immunology, 1998,95:427-436. 被引量:1
  • 5Hederer R A, Guntermann C, Miller N, et al. CD45 tyrosine phosphatase regulates Campadl-1H(CD52)-indueed TCR-depen- dent signal transducqion in human T cells[J]. Iut humunol. 2000.12:505-516. 被引量:1
  • 6Soares D P, Law M. Magnetic resonance spectroseopy of the brain: review of metabolites and clinical applications[J]. Clin Radiol, 2009,64(1):12-21. 被引量:1
  • 7Ginahli L. De Martinis M, Mfltfles E, el al. I,evels of expres- sion in mrnml and leukemic B and T ceils rela- lion with in vivt thertlpeflic respnes to tmpath-1H[J]. Leukemia Rles. 1998,22(2):185-191. 被引量:1
  • 8Quigley M M. Belhel K J, Sharpe R W, et al. CD52 expres- sion in hairy cell leukemia[J]. Am J Hematol. 2003,74(4):227- 230. 被引量:1
  • 9Rowan W. Tire J, Toplly P. et al. Cross-linking of the CAM- PATH-1 anligen(CD52) mediates growth inhibition in roman B- and F-lymphonm cell lines. and subseqtlenl emergence of CD52-deficienl cells[J]. ImmumAogy. 1998.95(3):427-436. 被引量:1
  • 10Klimler I Tuxen M K, Nielsen D I,, ct al. A systematic re- viev, of dual targeting in HER2-positiw breast cancer[J]. Caner Treatment Rev, 2013,9:1-12. 被引量:1

二级参考文献20

  • 1Osborne WL,Lennard AL.Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath-1H) or fludarabine[J].Haematologica,2005,90(1):ECR05 被引量:1
  • 2Quigley MM,Bethel KJ,Sharpe RW,et al.CD52 expression in hairy cell leukemia[J].Am J Hematol,2003,74(4):227-230. 被引量:1
  • 3Hale G,Cobbold S,Novitzky N,et al.On behalf of CAMPATH users,CAMPATH-1 antibodies in stem cell transplantation[J].Cytotherapy,2001,3:145-164. 被引量:1
  • 4Albitar M,Do KA,Johnson MM,et al.Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies[J].Cancer.2004,101(5):999-1008. 被引量:1
  • 5Rowan W,Tite J,Topley P,et al.Cross-linking of the CAMPATH-1 antigen(CD52) mediates growth inhibition in human B- and T-lymphoma cell lines,and subsequent emergence of CD52-deficient cells[J].Immunology,1998,95:427-436. 被引量:1
  • 6Hederer RA,Guntermann C,Miller N,et al.CD45 tyrosine phosphatase regulates Campath-1H(CD52)-induced TCR-dependent signal transduction in human T cells[J].Int Immunol,2000,12:505-516. 被引量:1
  • 7Nuckel H,Frey UH,Roth A,et al.Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity[J].Eur J Pharmacol.,2005,514(2-3):217-224. 被引量:1
  • 8Dyer MJS,Hale G.Effects of CAMPATH-1H in vivo in patients with lymphoid malignancies:influence of antibody isotype[J].Blood,1989,73:1431-1439. 被引量:1
  • 9Dearden CE,Matutes E,Cazin B,et al.High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H[J].Blood,2001,98:1721-1726. 被引量:1
  • 10Keating MJ,Flinn I,Jain V,et al.Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine:results of a large international study[J].Blood,2002,99:3554-3561. 被引量:1

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部